Tumor cell cytotoxicity of a novel metal chelator

Blood

Volumn 92, Issue 4, 1998, Pages 1384-1389

  Torti, S V ^a   Torti, F M ^b   Whitman, S R ^b   Brechbiel, M W ^b   Park, G ^b   Planalp, R P ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHELATING AGENT; COPPER; DEFEROXAMINE; IRON; MAGNESIUM; MANGANESE; TACHPYR; UNCLASSIFIED DRUG; ZINC;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHELATION; CYTOTOXICITY; DRUG SYNTHESIS; IRON STORAGE; PRIORITY JOURNAL;

EID: 0032529333     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1384     Document Type: Article

References (30)

1. Kemp JD, Cardillo T, Stewart BC, Kchrbcrg E, Weiner G, Hedlund B, Naumann PW: Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. Cancer Res 55:3817, 1995
2. Kovar J. Stunz L, Stewart BC, Kriegerbeckova K, Ashman RF, Kemp JD: Direct evidence that iron deprivation induces apoptosis in murine lymphoma. Pathobiology 65:61, 1997
3. Donfrancesco A, Deb G, DeSio L, Cozza R, Castellano A: Role of deferoxamine in tumor therapy. Acta Haematol 95:66, 1996
4. Frantz CN, Bernstein M, Cstelberry R, Vietti T: Dose escalation of desferrioxamine (DFO) in children with refractory neuroblastoma: A Pediatric Oncology Group study. Proc Am Soc Clin Oncol 13:416, 1994 (abstr)
5. Miller RS, Torti FM: Chemotherapy of advanced transitional-cell carcinoma of the bladder. Cancer Chemother Pharmacol 30:899, 1992 (suppl)
6. Einhorn LH, Roth BJ, Ansari R, Deter R, Gonin R, Loehrer PJ: Phase II trial of vinbastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12:2271, 1994
7. Chitambur CR, Zahir SA, Ritch PS, Anderson T: Evaluation of continuous-infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. Amer J Clin Oncol 20:173, 1997
8. Hann HW, Stahlhut MW, Rubin R, Maddrew WC: Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 70:2051, 1992
9. Seligman PA, Schleicher RB, Siriwardana G, Domenico J, Gelfand EW: Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. Blood 82:1608, 1993
10. Hsieh-Ma ST, Shi T, Reeder J, Ring DB: In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin Immunol Immunopathol 80:185, 1996
11. Hofforand AV: Prospects for oral iron chelation therapy. J Lab Clin Med 123:492, 1994
12. Ponka P, Borova J, Neuwirt J, Fuchs O: Mobilization of iron from reticulocytes. Febs Lett 97:317, 1979
13. Richardson DR, Tran EH, Ponka P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295, 1995
14. Bowen T, Planalp RP, Brechbiel MW: An improved synthesis of cis, cis-1,3,5-triaminocyclohexane. Bioorg Med Chera Lett 6:807, 1996
15. 3 , M = Ga, In) of N, N′, N″-Tris(2-pyridylmethyl)-cis-1,3,5-Triaminocyclohexane: Preparation and structure. Inorg Chem 3:4600, 1997
16. Ye N, Rogers RD, Brechbiel MW, Planalp RP: Synthesis and X-ray crystal structure of N,N′,N″-tris(2-thienylmethyl)-cis-1,3,5-triaininocyclohexane copper(II) dichloride. Polyhedron 17:603, 1998
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth 65:55, 1983
18. Torti SV, Kwak EL, Miller SC, Miller LL, Ringold GM, Myambo KB, Young AP, Torti FM: The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem 263: 12638, 1988
19. Bruggemann SK, Kisro J, Wagner T: Ifosfamide cytotoxicity on human tumor and renal cells: Role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 57:2676, 1997
20. Silber R. Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M: Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine and camptothecin analogs. Blood 84: 3440, 1994
21. Rogers J, Munro H: Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells. Proc Natl Acad Sci USA 84:2277, 1987
22. Galey JB: Potential use of iron chelators against oxidative damage. Adv Pharmacol 38:167, 1997
23. Stein WD: Transport and Diffusion Across Cell Membranes. Orlando, FL, Academic Press, 1986
24. Huheey, JE, Keiter EA, Keiter RL in Inorganic Chemistry: Principle of Structure and Reactivity. New York, NY, Harper, 1993, pp 347
25. Rouault T, Hentze M, Caughman SW, Harford J, Klausner R: Binding of a cystolic protein to the iron-responsive element of human ferritin messenger RNA. Science 241:1207, 1988
26. Waiden WE, Daniels-McQueen S, Brown PH, Gaffield L, Russell DA, Bielser D, Bailey LC, Thach RE: Translational repression in eukaryotes: Partial purification and characterization of a repressor of ferritin mRNA translation. Proc Natl Acad Sci USA 85:9503, 1988
27. Leibold EA, Munro HN: Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5′ untranslated region of ferritin heavy-and light-subunit mRNAs. Proc Natl Acad Sci USA 85:2171, 1988
28. Seymour GJ, Walsh MD, Lavin MF, Struitton G, Gardiner RA: Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 15:341, 1987
29. Fujiwara M: Expression of transform receptor on transitional cell cancer. Acta Urol Jpn 37:11, 1991
30. Seligman PA, Moran PL, Schleicher RB, Crawford ED: Treatment with gallium nitrate: Evidence for interference with iron metabolism in vivo. Amer J Hematol 41:232, 1992